The Technical Analyst
Design Therapeutics, Inc. [DSGN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Design Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.27% $3.65
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 204.41 mill |
| EPS: | -1.290 |
| P/E: | -2.83 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 56.00 mill |
| Avg Daily Volume: | 0.264 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.83 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.48x |
| Company: PE -2.83 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0003 (-99.99%) $-3.65 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.40 - 3.90 ( +/- 6.93%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Schmid John P. | Buy | 17 809 | Common Stock |
| 2024-03-22 | Schmid John P. | Buy | 9 156 | Common Stock |
| 2024-03-25 | Berger Heather A. | Buy | 1 300 | Common Stock |
| 2024-03-13 | Kim Jae B. | Sell | 0 | Common Stock |
| 2024-03-13 | Kim Jae B. | Sell | 315 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 76.51 |
| Last 96 transactions |
| Buy: 40 774 561 | Sell: 39 424 073 |
Forecast:
16:00 - $3.66
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.66
Forecast 2: 16:00 - $3.66
Forecast 3: 16:00 - $3.66
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.65 (-0.27% ) |
| Volume | 0.191 mill |
| Avg. Vol. | 0.264 mill |
| % of Avg. Vol | 72.49 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DSGN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DSGN
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Latest Press Releases
2024-03-19 16:01:00 - Press Release
Design Therapeutics Outlines Progress Across Genetac™ Platform And Announces Fourth Quarter And Full Year 2023 Financial Results
New drug product for friedreich ataxia (fa) dt-216p2 with favorable nonclinical pharmacokinetic and injection site safety profile; complete glp studies by year-end 2024 to start patient trials in 2025
2024-03-12 06:30:00 - Press Release
Design Therapeutics To Webcast Fourth Quarter And Full Year 2023 Financial Results And Comprehensive Portfolio Update
Carlsbad, calif., march 12, 2024 (globe newswire) -- design therapeutics, inc. (nasdaq: dsgn), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on tuesday, march 19, 2024, at 4:30 p.m. et to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.
2023-11-13 16:05:00 - Press Release
Design Therapeutics Reports Third Quarter 2023 Financial Results And Plans For A Comprehensive Portfolio Update In Early 2024
Seasoned biotech executive pratik shah appointed as chief executive officer to lead company turnaround current cash and securities of ~$290m support extended five-year operating runway through 2028 revised corporate strategy with realignment towards long-term growth to be presented in early 2024; additional details to follow carlsbad, calif., nov. 13, 2023 (globe newswire) -- design therapeutics, inc. (nasdaq: dsgn), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results.
2023-10-09 19:02:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Design Therapeutics, Inc. - Dsgn
New york , oct. 9, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of design therapeutics, inc. ("design" or the "company") (nasdaq: dsgn). such investors are advised to contact robert s.
2023-09-29 18:54:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Design Therapeutics, Inc. - Dsgn
New york , sept. 29, 2023 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of design therapeutics, inc. ("design" or the "company") (nasdaq: dsgn).
Latest News
2024-03-12 06:30:00 - GlobeNewsWire
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.
2023-12-18 13:32:15 - Zacks Investment Research
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-08-15 15:02:00 - The Motley Fool
Why Shares of Design Therapeutics Are Plummeting on Tuesday
Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026.
2023-08-15 08:17:00 - Market Watch
Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stage trial of a treatment for Friedreich ataxia, a genetic neuromuscular disease. The phase 1 trial of the treatment, DT-216, confirmed clinical activity in patients with the disease but also found injection-site reactions, the company said in a release late Monday.
2023-05-31 06:30:00 - GlobeNewsWire
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 p.m. ET in NYC.
2023-04-24 06:30:00 - GlobeNewsWire
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company's novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orleans from April 23-27, 2023.
2023-04-11 09:55:20 - InvestorPlace
Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down
Sorry to be the bearer of bad news, but Design Therapeutics (NASDAQ: DSGN ) has good intentions and less-than-stellar financials. Design Therapeutics may be a pioneer in the field of genomic medicine, and that's commendable.
2023-03-27 17:03:56 - InvestorPlace
Short Squeeze Stocks: BBBY, SI and 3 Other Stocks Ready to Squeeze
Short squeeze stocks are the talk of Wall Street at the moment. As the banking crisis continues to unfold, some investors are seeking refuge by betting against many well-known losers — and reaping tremendous gains.
2022-10-17 16:05:00 - GlobeNewsWire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022
2022-09-22 06:30:00 - GlobeNewsWire
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC.